# Harbour BioMed Announces NMPA Approval of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors

- Link: https://www.thailand-business-news.com/pr-news/harbour-biomed-announces-nmpa-approval-of-ind-application-for-hbm7004-for-the-treatment-of-advanced-solid-tumors
- Published: 2026-08-18T16:02:00+07:00
- Author: PR Newswire

|   |

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 18, 2026 /PRNewswire/—
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company 
committed to the discovery and development of novel antibody therapeutics in immunology,
oncology and other disease areas, today announced that the National Medical Products
Administration (NMPA) of China has approved the Investigational New Drug (IND) application
for HBM7004 for the treatment of advanced solid tumors.

HBM7004 is a novel B7H4xCD3 bispecific antibody developed using the Company’s HBICE
^(®) platform. This bispecific antibody is designed to provide a differentiated 
approach to cancer immunotherapy with the potential to enhance both efficacy and
safety. The development of HBM7004 further demonstrated the HBICE^(®) platform’s
versatility and plug-and-play advantages. In preclinical studies, HBM7004 demonstrated
an intratumor B7H4-dependent T cell activation manner. In multiple animal models,
HBM7004 showed strong anti-tumor efficacy, remarkable _in vivo_ stability, and reduced
systemic toxicity. Additionally, in preclinical models, HBM7004 exhibited a strong
synergistic effect when combined with a B7H4x4-1BB bispecific antibody at a low 
effector-to-target cell ratio, indicating an encouraging therapeutic window.

"We are very pleased to receive NMPA approval of IND application for HBM7004, which
marks another important milestone in our commitment to advancing novel immunotherapies
for patients with advanced solid tumors," said Dr. Jingsong Wang, Founder, Chairman
and Chief Executive Officer of Harbour BioMed. "This approval, together with the
recent FDA clearance, underscores the strength of our HBICE^(®) platform and its
ability to generate differentiated bispecific candidates with promising preclinical
profiles. We are now one step closer to bringing HBM7004 into the clinic in China,
and we look forward to advancing this program to address the needs of cancer patients
with limited treatment options."

**About Harbour BioMed**

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to 
the discovery and development of novel antibody therapeutics in immunology, oncology
and other areas. The Company is building a robust portfolio and differentiated pipeline
through internal R&D capability, strategic global collaborations in co-discovery
and co-development, and selective acquisitions.

Our proprietary antibody technology platform, Harbour Mice^(®), generates fully 
human monoclonal antibodies in both the conventional two heavy and two light chain(
H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies,
the HCAb-based immune cell engagers (HBICE^(®)) bispecific antibody technology enables
tumor-killing effects that traditional combination therapies cannot achieve. The
HCAb-based Antibody Plus technology (HCAb PLUS^(TM)) provides comprehensive modality
solutions for the development of innovative multi-specific medicines in different
disease areas. Additionally, building upon the Harbour Mice^(®) platform, Harbour
BioMed launched its first fully human Generative AI HCAb Model powered by its Hu-
mAtrIx^(TM) AI platform, accelerating the development of innovative therapies.

By integrating Harbour Mice^(®), HBICE^(®), HCAb PLUS^(TM), a single B-cell cloning
platform and AI technologies, Harbour BioMed has built a highly efficient and distinctive
antibody discovery engine for developing next-generation therapeutic antibodies.
For more information, please visit [www.harbourbiomed.com](http://www.harbourbiomed.com/).

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Harbour BioMed Announces NMPA Approval of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors ](http://www.prnasia.com/story/archive/5028380_CN28380_0?rand=184833)
